LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 345

Search options

  1. Article ; Online: Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.

    Logothetis, Christopher J / Hahn, Andrew W

    European urology

    2024  

    Language English
    Publishing date 2024-03-26
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2024.03.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome.

    Logothetis, Christopher J / Hahn, Andrew W

    European urology

    2023  Volume 85, Issue 1, Page(s) 3–7

    Abstract: There is a need to understand what accounts for the modest impact of therapy on overall survival among men with potentially lethal prostate cancer. Given converging lines of evidence, we hypothesize that in a subset of men, prostate cancer is part of an " ...

    Abstract There is a need to understand what accounts for the modest impact of therapy on overall survival among men with potentially lethal prostate cancer. Given converging lines of evidence, we hypothesize that in a subset of men, prostate cancer is part of an "overlap syndrome" of age-related illnesses with shared biologic vulnerability.
    MeSH term(s) Male ; Humans ; Prostatic Neoplasms ; Syndrome
    Language English
    Publishing date 2023-05-18
    Publishing country Switzerland
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2023.04.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Improved Outcomes in Men with Advanced Prostate Cancer.

    Logothetis, Christopher J

    The New England journal of medicine

    2017  Volume 377, Issue 4, Page(s) 388–390

    MeSH term(s) Humans ; Male ; Prostatic Neoplasms
    Language English
    Publishing date 2017--27
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMe1704992
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book: Docetaxel (Taxotere)

    Amin, Pradip / Logothetis, Christopher J.

    current status and future directions in prostate cancer

    (Seminars in oncology ; 28,4, Suppl. 15)

    2001  

    Author's details Christopher J. Logothetis, guest ed. Contributors Pradip Amin
    Series title Seminars in oncology ; 28,4, Suppl. 15
    Collection
    Language English
    Size 85 S. : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    HBZ-ID HT013183202
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  5. Article ; Online: Prostate cancer bone metastases: not so systemic after all.

    Logothetis, Christopher J

    The Lancet. Oncology

    2014  Volume 15, Issue 7, Page(s) 675–676

    MeSH term(s) Bone Neoplasms/radiotherapy ; Bone Neoplasms/secondary ; Humans ; Male ; Prostatic Neoplasms, Castration-Resistant/pathology ; Radium/therapeutic use
    Chemical Substances Radium (W90AYD6R3Q)
    Language English
    Publishing date 2014-06
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(14)70217-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers.

    Tu, Shi-Ming / Campbell, Matthew / Shah, Amishi / Logothetis, Christopher J

    Journal of cell science & therapy

    2021  Volume 12, Issue 6

    Abstract: When we aspire to cure cancer, we may need to search no further than a curable cancer, such as Germ Cell Tumor of the Testis (TGCT). After all, a germ cell is a primordial stem cell. Importantly, TGCT provides a classic stem cell model of cancer that ... ...

    Abstract When we aspire to cure cancer, we may need to search no further than a curable cancer, such as Germ Cell Tumor of the Testis (TGCT). After all, a germ cell is a primordial stem cell. Importantly, TGCT provides a classic stem cell model of cancer that teaches us some invaluable lessons about curing other intractable solid tumors. The intrinsic intratumoral heterogeneity of TGCT alludes to its stem-ness origin and nature. Which implicates the existence of putative lethal TGCT subtypes-the identification and detection of which may further enhance the cure rate and improve the therapeutic ratio of TGCT. In this Mini review, we discuss about the role of biologic insights, clinical lessons, and therapeutic strategies in drug and therapy development. We illustrate some clinical pearls and perils when it concerns drug versus therapy development in the cure and care of patients with TGCT. In many respects, we have cured more TGCT patients when we apply multimodal therapy rather than targeted therapy and integrated medicine rather than precision medicine. In principle and in practice, this is the implication of therapy versus drug development in improving the overall outcome and cure rate of patients with cancer.
    Language English
    Publishing date 2021-08-08
    Publishing country United States
    Document type Journal Article
    ISSN 2157-7013
    ISSN 2157-7013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Treatment of castrate-resistant prostate cancer.

    Logothetis, Christopher J

    The Journal of urology

    2013  Volume 190, Issue 2, Page(s) 439–440

    MeSH term(s) Androgen Antagonists/administration & dosage ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Immunotherapy/methods ; Male ; Prostatic Neoplasms/drug therapy
    Chemical Substances Androgen Antagonists ; Antineoplastic Agents
    Language English
    Publishing date 2013-08
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1016/j.juro.2013.05.041
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

    Logothetis, Christopher J

    European urology

    2013  Volume 64, Issue 1, Page(s) 170

    MeSH term(s) Carcinoma, Renal Cell/genetics ; Evolution, Molecular ; Genetic Heterogeneity ; Humans ; Kidney Neoplasms/genetics ; Phenotype
    Language English
    Publishing date 2013-07
    Publishing country Switzerland
    Document type Comment ; Journal Article
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2013.04.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer.

    Vardaki, Ioulia / Özcan, Seda Sabah / Fonseca, Pedro / Lin, Sue-Hwa / Logothetis, Christopher J / Yachnin, Jeffrey / Ullen, Anders / Panaretakis, Theocharis

    The Prostate

    2023  Volume 83, Issue 10, Page(s) 950–961

    Abstract: Background: Prostate cancer is the second most common cancer type and the second most common cancer-related cause of death in men. Cabazitaxel, a next-generation taxane, shows favorable toxicity profile and is effective in docetaxel-resistant tumors. ... ...

    Abstract Background: Prostate cancer is the second most common cancer type and the second most common cancer-related cause of death in men. Cabazitaxel, a next-generation taxane, shows favorable toxicity profile and is effective in docetaxel-resistant tumors. Despite initial responses, in most cases, prostate cancer patients acquire resistance to cabazitaxel. There is a need to identify molecular markers that can monitor and predict treatment response.
    Methods: We performed transcriptional exosome profiling (Human Transcriptome Array-HTA 2.0) from the plasma of 19 patients with castration-resistant prostate cancer at baseline and in patients after one cycle of cabazitaxel (C1). The patients were stratified in two groups (responders and nonresponders) according to their clinical response to cabazitaxel. Gene set enrichment analysis and ingenuity pathway analysis platforms were used for gene and pathway analysis.
    Results: We detected molecular differences in the exosomes from two groups of patients (nonresponders vs. responders) at baseline in pathways related to prostate cancer, oncogenic signaling, cytoskeleton, and immune system. In nonresponders, we found enrichment of cytoskeleton related gene (Stathmin-1 and ITSN1) that have been associated with resistance to cabazitaxel. Monitoring of exosomal transcripts after the first cycle of treatment revealed changes in pathways associated with response to treatment.
    Conclusions: Sequential transcriptional profiling of plasma-derived exosomes reveals differential expression of genes that may reflect resistance to cabazitaxel treatment and therapy response.
    MeSH term(s) Male ; Humans ; Transcriptome ; Exosomes/genetics ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Taxoids/pharmacology ; Taxoids/therapeutic use ; Treatment Outcome
    Chemical Substances cabazitaxel (51F690397J) ; Taxoids
    Language English
    Publishing date 2023-04-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604707-5
    ISSN 1097-0045 ; 0270-4137
    ISSN (online) 1097-0045
    ISSN 0270-4137
    DOI 10.1002/pros.24536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.

    Paindelli, Claudia / Parietti, Vanessa / Barrios, Sergio / Shepherd, Peter / Pan, Tianhong / Wang, Wei-Lien / Satcher, Robert L / Logothetis, Christopher J / Navone, Nora / Campbell, Matthew T / Mikos, Antonios G / Dondossola, Eleonora

    Acta biomaterialia

    2024  Volume 178, Page(s) 83–92

    Abstract: Bone metastases are the most common milestone in the lethal progression of prostate cancer and prominent in a substantial portion of renal malignancies. Interactions between cancer and bone host cells have emerged as drivers of both disease progression ... ...

    Abstract Bone metastases are the most common milestone in the lethal progression of prostate cancer and prominent in a substantial portion of renal malignancies. Interactions between cancer and bone host cells have emerged as drivers of both disease progression and therapeutic resistance. To best understand these central host-epithelial cell interactions, biologically relevant preclinical models are required. To achieve this goal, we here established and characterized tissue-engineered bone mimetic environments (BME) capable of supporting the growth of patient-derived xenograft (PDX) cells, ex vivo and in vivo. The BME consisted of a polycaprolactone (PCL) scaffold colonized by human mesenchymal stem cells (hMSCs) differentiated into osteoblasts. PDX-derived cells were isolated from bone metastatic prostate or renal tumors, engineered to express GFP or luciferase and seeded onto the BMEs. BMEs supported the growth and therapy response of PDX-derived cells, ex vivo. Additionally, BMEs survived after in vivo implantation and further sustained the growth of PDX-derived cells, their serial transplant, and their application to study the response to treatment. Taken together, this demonstrates the utility of BMEs in combination with patient-derived cells, both ex vivo and in vivo. STATEMENT OF SIGNIFICANCE: Our tissue-engineered BME supported the growth of patient-derived cells and proved useful to monitor the therapy response, both ex vivo and in vivo. This approach has the potential to enable co-clinical strategies to monitor bone metastatic tumor progression and therapy response, including identification and prioritization of new targets for patient treatment.
    MeSH term(s) Male ; Humans ; Xenograft Model Antitumor Assays ; Bone and Bones/pathology ; Bone Neoplasms/therapy ; Bone Neoplasms/secondary ; Prostatic Neoplasms/pathology ; Osteoblasts/pathology
    Language English
    Publishing date 2024-02-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2173841-5
    ISSN 1878-7568 ; 1742-7061
    ISSN (online) 1878-7568
    ISSN 1742-7061
    DOI 10.1016/j.actbio.2024.02.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top